# Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

> **NCT00013585** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 127 (actual)

## Conditions studied

- Cognition Disorders
- HIV Infections

## Interventions

- **DRUG:** Selegiline hydrochloride

## Key facts

- **NCT ID:** NCT00013585
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2021-11-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00013585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00013585, "Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00013585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*